You are viewing the site in preview mode

Skip to main content

Table 6 Neutrophil and monocyte immunophenotypic scores, and total myeloid score for myelodysplasia in the PB from LR-MDS patients versus normal individuals (controls), taking in account the number of phenotypic abnormalities found in each case

From: A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the “MDS thermometer”

  LR-MDS
(n = 14) 		Controls
(n = 14)
Neutrophil immunophenotypic score 1 (0–8)
 Score 5 (0–8) 0 (0–1)
 Score rank (Σ) 59 1
 Score classes
  0 (no dysplasia) 1 (7%) 13 (93%)
  1 (possible dysplasia) 0 (0%) 1 (7%)
  2–3 (mild dysplasia) 3 (21%) 0 (0%)
  4–6 (moderate dysplasia) 9 (64%) 0 (0%)
  7–8 (severe dysplasia) 1 (7%) 0 (0%)
Monocyte immunophenotypic score 1 (0–2)
 Score 1 (0–2) 0 (0–1)
 Score rank (Σ) 15 2
 Score classes
  0 (no dysplasia) 2 (14%) 12 (86%)
  1 (possible dysplasia) 8 (57%) 2 (14%)
  2 (dysplasia) 4 (29%) 0 (0%)
Myeloid immunophenotypic score 1 (0–10)
 Score 6 (0–8) 0 (0–1)
 Score rank (Σ) 74 3
 Score classes
  0 (no dysplasia) 1 (7%) 11 (79%)
  1 (possible dysplasia) 0 (0%) 3 (21%)
  2–4 (mild dysplasia) 3 (21%) 0 (0%)
  5–7 (moderate dysplasia) 7 (50%) 0 (0%)
  8–10 (severe dysplasia) 3 (21%) 0 (0%)
  1. Abbreviations: LR-MDS lower risk myelodysplastic syndromes, PB peripheral blood
  2. Results are expressed as absolute and (relative) frequencies or as median (range) values
  3. Percentages were approximated to the closest full unit
  4. Neutrophil score: The following parameters were considered: FSC, SSC, CD10, CD11b, CD11c, CD13, CD16, and CD45. Each abnormally low parameter (< mean – 2D of the values observed in controls) was scored with 1 point. Values within the mean ± SD or above the mean + 2SD were scored with “0”
  5. Monocyte score: The following parameters were considered: % of CD16+ monocytes and % of CD56+ monocytes. These parameters were scored as follows: CD14 + CD56+ monocytes: ≤18% (0 points); > 18% (1 point); CD14 + CD16+ monocytes: ≥5% (0 points); < 5% (1 point)
  6. Myeloid score: obtained by adding up the neutrophil and the monocytic score achieved for each patient
  7. The following score rankings were obtained for each of the parameters analyzed: Patients: FSC = 10; CD11b = 10; CD11c = 10; CD10 = 9; SSC = 8; CD13 = 4; CD15 = 0; CD16 = 6; CD45 = 2. Controls: CD15 = 1; CD45 = 1; other parameters = 0
Back to article page

BMC Hematology

ISSN: 2052-1839

Contact us